Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) announced today the nomination of Dr. Wolfgang Hofmann for election as an independent member of its Supervisory Board at the upcoming Annual General Meeting (AGM) scheduled for June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board, as well as a proposal to increase the board size from six to seven members.
In a separate development, Evotec has entered into a cooperation agreement with MAK Capital Fund LP, a key shareholder, following constructive discussions. Under the terms of the agreement, MAK Capital has agreed to customary voting and cooperation commitments. This move reflects Evotec’s commitment to open shareholder dialogue and aligns with its efforts to strengthen oversight and governance.
Prof. Dr. Iris Low-Friedrich, Chairwoman of Evotec’s Supervisory Board, commented: “We are pleased to nominate Wolfgang for election at the upcoming AGM. His appointment would contribute oversight and governance capabilities through additional industry, scientific and governance expertise, complementing our existing Board structure as we continue to implement our transformation plans to grow shareholder value. The agreement reached reflects Evotec’s commitment to constructive shareholder engagement, supporting the long‑term success of the Company.”
Michael A. Kaufman, Chief Executive Officer of MAK Capital, said: “We appreciate the constructive dialogue and welcome Wolfgang’s nomination to the Supervisory Board. We look forward to continuing our collaboration with the Supervisory Board and Management Board to support Evotec's ongoing transformation.”
The nomination of Dr. Wolfgang Hofmann and the expansion of the Supervisory Board underscore Evotec's focus on enhancing governance and oversight as it executes its transformation plans. The cooperation agreement with MAK Capital signals a positive resolution to shareholder discussions, potentially setting a precedent for future engagements. For Evotec, which partners with all top 20 pharma companies and over 800 biotechs, strong governance is critical to maintaining investor confidence and advancing its drug discovery and development pipeline.
The AGM vote on these appointments and the board expansion will be closely watched by investors, as they are expected to support effective oversight and long-term value creation. The changes come at a pivotal time for Evotec, which is leveraging AI-driven innovation and platforms like iPSC-based disease modeling to accelerate drug development. Analysts suggest that the enhanced board composition could improve strategic decision-making, benefiting the company's more than 100 proprietary R&D assets.
For more information about Evotec, visit www.evotec.com and follow on LinkedIn and X/Twitter @Evotec.
